Breaking News

US Department of Labor releases informational copies of 2022 Form 5500 Series Annual Return/Report Two Men Wanted on Charges of Aggravated Sex Crimes Nabbed at the Progreso Port of Entry Secretary Walsh announces new partners, action plan, support for international worker voice initiative False Name Turns into Counterfeit U.S. Currency Discovery by Wellesley Island Border Patrol Agents US Department of Labor awards $5M to help fight workplace discrimination, harassment; empower working women in Nigeria, Liberia El Paso CBP Officers Apprehend Fugitive Wanted for Homicide US Department of Labor recovers more than $17K for illegally terminated employee after Publix Super Markets Inc. violates medical leave protections CBP Seizes Fentanyl and Methamphetamine at Presidio Port

Issued:  Tuesday 06 October 2009, London, UK

GSK is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.

The company today provided an update on orders received for its pandemic (H1N1) adjuvanted vaccine.

On the 4th August, GSK confirmed that it had contracts in place to supply 291 million doses of the vaccine and had a variety of agreements in place with the US Government to supply pandemic products worth $250 million. 

Since that date, 22 government orders have been agreed to supply a further 149 million doses of the vaccine.  This now brings the total number of doses ordered for GSK’s pandemic vaccines to 440 million.  Discussions continue with governments for further supplies.

First supplies of the vaccine will be shipped to governments during the week commencing 5th October. Shipments of the vaccine will be delivered in both the fourth quarter of 2009 and the first half of 2010.

The vaccine deliveries are contingent on a number of factors including government import/export regulations, regulatory approvals, approvals for outsourced packaging and filling as well as testing required by reference laboratories. 

GSK will continue to provide regular updates to governments relating to delivery schedules to support them in planning their vaccination programmes.

Further information on GSK’s development of vaccines to protect against pandemic (H1N1) 2009, including explanation of the development process and background information on adjuvants is available on: www.gsk.com/media/pandemic-flu.htm

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

Enquiries:

   

UK Media enquiries:

Philip Thomson

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Gwenan White

(020) 8047 5502

 

 

 

US Media enquiries:

Nancy Pekarek

(919) 483 2839

 

Mary Anne Rhyne

(919) 483 2839

 

Kevin Colgan

(919) 483 2839

 

Lisa Behrens

(919) 483 2839

 

   

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

 

Sally Ferguson

(020) 8047 5543

 

Gary Davies

(020) 8047 5503

     

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

 

Jen Hill Baxter

(215) 751 7002

               

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2008.

Source link